The U.S. Food and Drug Administration (FDA) issues a show-cause notice to Hindustan Antibiotics Limited concerning alleged serious manufacturing lapses at its Pimpri facility. According to reporting, the notice is connected to critical deficiencies observed in operations, and it is accompanied by regulatory action affecting the company’s ability to operate. The FDA asks the firm to respond to the allegations and explain why enforcement measures should not be taken. The notice follows inspections or review findings that the regulator describes as significant. The company’s operations at the site are reported to have been halted as the matter proceeds. The show-cause process is intended to provide the manufacturer an opportunity to address the cited issues or present corrective actions and justifications. Until the regulator reviews the company’s response, the enforcement implications of the notice remain under consideration.